You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 163 No. 2, January 27, 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Investigation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (92)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Viral Infections
 •Prognosis/ Outcomes
 •Liver/ Biliary Tract/ Pancreatic Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Validity and Clinical Utility of the Aspartate Aminotransferase–Alanine Aminotransferase Ratio in Assessing Disease Severity and Prognosis in Patients With Hepatitis C Virus–Related Chronic Liver Disease

Edoardo Giannini, MD; Domenico Risso, MD; Federica Botta, MD; Bruno Chiarbonello, MD; Alberto Fasoli, MD; Federica Malfatti, MD; Paola Romagnoli, MD; Emanuela Testa, MD; Paola Ceppa, MD; Roberto Testa, MD

Arch Intern Med. 2003;163:218-224.

Background  The aspartate aminotransferase–alanine aminotransferase ratio (AST/ALT ratio) has been used to noninvasively assess the severity of disease in patients with chronic liver disease (CLD). We previously demonstrated that progressive liver functional impairment is associated with an increase in the AST/ALT ratio.

Objectives  To evaluate the reproducibility and transportability of the AST/ALT ratio in a large cohort of patients with different degrees of hepatitis C virus (HCV)–related CLD, to confirm the correlation between progressive impairment of liver function and increase in the AST/ALT ratio, to evaluate whether diagnostic accuracy of the ALT/AST ratio can be improved by using it with other biochemical variables, and to assess the 1-year prognostic capability of the AST/ALT ratio in patients with liver cirrhosis.

Patients and Methods  We retrospectively evaluated 252 patients with HCV-related CLD. The AST/ALT ratio was correlated with the degree of liver fibrosis in patients with chronic hepatitis and with the Child-Pugh score in patients with cirrhosis. All patients had undergone monoethylglycinexylidide (MEGX) testing to evaluate liver function. We assessed the prognostic ability of the AST/ALT ratio in a subset of 63 cirrhotic patients who were followed up for at least 1 year.

Results  The AST/ALT ratio was more frequently 1 or higher in cirrhotic patients (P<.001). There was a significant correlation between MEGX values and the AST/ALT ratio (rs = -0.621, P<.001). Multivariate stepwise logistic analysis showed that AST/ALT ratio, platelet count (PLT), MEGX values, and prothrombin activity were independently associated with the presence of cirrhosis. Combined assessment of the AST/ALT ratio and/or PLT obtained 97.0% positive predictive value and 97.9% negative predictive value for the diagnosis of cirrhosis. The AST/ALT ratio had 81.3% sensitivity and 55.3% specificity in identifying cirrhotic patients who died within 1-year of follow-up.

Conclusions  The AST/ALT ratio is both reproducible and transportable in patients with HCV-related CLD. The AST/ALT ratio is correlated with both histologic stage and clinical evaluation. Progressive liver functional impairment is reflected by an increase in the AST/ALT ratio. Noninvasive evaluation by means of the combined AST/ALT ratio and PLT assessment misclassifies only a few cirrhotic patients. In cirrhotic patients, the AST/ALT ratio provides medium-term prognostic information that is no different from that provided by established prognostic scores.


From the Gastroenterology Unit and Postgraduate School of Gastroenterology and Digestive Endoscopy, Departments of Internal Medicine (Drs Giannini, Botta, Chiarbonello, Fasoli, Malfatti, Romagnoli, E. Testa, and R. Testa), Health Sciences (Dr Risso), and Pathology (Dr Ceppa), University of Genoa, Genoa, Italy.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

31P MR Spectroscopy in Assessment of Response to Antiviral Therapy for Hepatitis C Virus Related Liver Disease
Lim et al.
Am. J. Roentgenol. 2007;189:819-823.
ABSTRACT | FULL TEXT  

Relationship between Hepatitis C and Chronic Kidney Disease: Results from the Third National Health and Nutrition Examination Survey
Tsui et al.
J. Am. Soc. Nephrol. 2006;17:1168-1174.
ABSTRACT | FULL TEXT  

Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study
Foucher et al.
Gut 2006;55:403-408.
ABSTRACT | FULL TEXT  

Hepascore: An Accurate Validated Predictor of Liver Fibrosis in Chronic Hepatitis C Infection
Adams et al.
Clin. Chem. 2005;51:1867-1873.
ABSTRACT | FULL TEXT  

Liver enzyme alteration: a guide for clinicians
Giannini et al.
CMAJ 2005;172:367-379.
ABSTRACT | FULL TEXT  

Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the 'acute' type
Ferrari et al.
QJM 2004;97:407-412.
ABSTRACT | FULL TEXT  

HIGH AST/ALT RATIO MAY INDICATE ADVANCED ALCOHOLIC LIVER DISEASE RATHER THAN HEAVY DRINKING
NYBLOM et al.
Alcohol Alcohol 2004;39:336-339.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.